Plain-English translation of NCT06227117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether Disitamab Vedotin—a newer type of cancer drug—works better when combined with other medications like toripalimab (which helps your immune system fight cancer) and/or chemotherapy. The goal is to shrink breast tumors before surgery in people with a specific type of breast cancer that doesn't respond to hormone or HER2-targeted treatments.
Some breast cancers don't respond well to standard hormone or HER2 treatments, leaving patients with fewer options. This trial is exploring whether combining this new medication with immune-boosting drugs or traditional chemotherapy can help more patients achieve complete tumor shrinkage before surgery, which may improve their long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three treatment groups, each receiving different combinations of medications before your planned breast surgery. You'll receive infusions or injections of the treatment drugs over several weeks to months, with regular visits to the clinic for blood tests, scans, and heart monitoring to make sure the treatment is working and safe. After completing the pre-surgery treatment phase, you'll have surgery to remove the tumor, and the doctors will assess how well the medication worked.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
China